Drug and Alcohol Dependence
Volume 58, Issue 1 , Pages 3-7 , 1 February 2000

An approach to the medical marijuana controversy

  • L.E Hollister

      Affiliations

    • Corresponding Author InformationTel.: +1-713-7421-7809; fax: +1-713-741-7809

Received 30 November 1998 ,Revised 21 June 1999 ,Accepted 24 June 1999.

References 

  1. Agurell S, Halldin M, Lindgren J-E, Ohlsson A, Widman M, Gillespie H, et al. Pharmacokinetics and metabolism of δ-1-tetrahydrocannibinol and other cannabinoids with the emphasis on man. Pharmacol. Rev. 1986;38:21–43
  2. Beal J, Olsen R, Shepherd KV, Plasse T. Effect of dronabinol on appetite and weight in AIDS; long-term follow-up. Proceedings of the IX International Conference on AIDS, Berlin. 1993;
  3. Beal JF, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 1995;10:89–97
  4. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J. Pain Symptom Manage. 1997;14:7–14
  5. Benson JA, Watson SJ. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Institute of Medicine; 1999;
  6. Chang AE, Shiling DJ, Stillman RC, Goldberg N, Seipp C, Barofsky I, et al. Delta-9-tetrahydrocannabinoal as an antiemetic in cancer patients receiving high-dose methotrexate; a prospective, randomized evaluation. Ann. Int. Med. 1979;19:819–824
  7. Doblin RE, Kleiman MAR. Marijuana as antiemetic medicine; A Survey of oncologist’s experiences and attitudes. J. Clin. Oncol. 1991;9:1313–1319
  8. Foltin RW, Brady JV, Fischman M. Behavioral analysis of marijuana effect on food I intake in normals. Pharmacol. Biochem. Behav. 1986;25:573–582
  9. Frytak S, Moertel C, O’Fallon J, Rubin J, Creagan E, Schutt O’Connell M, et al. 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. Ann. Int. Med. 1979;91:825–830
  10. Gorter R. Management of anorexia-cachexia associated with cancer and HIV infection. Oncology. 1991;5(Suppl 9):13–16
  11. Grinspoon L, Bakalar B. Marijuana as medicine. A plea for reconsideration. J. Am. Med. Assoc. 1996;273:1875–1876
  12. Gross H, Ebert MH, Faden VB, Goldberg SC, Kay WH, Caine ED, et al. A double-blind trial of δ-9-tetrahydrocannabinol in primary anorexia nervosa. J. Clin. Psychopharmacol. 1983;3:165–171
  13. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. New Engl. J. Med. 1979;300:1295–1298
  14. Hollister LE. Hunger and appetite after single doses of marijuana, alcohol and amphetamine. Clin. Pharmacol. Ther. 1971;12:44–49
  15. Hollister LE. Health aspects of cannabis. Pharmacol. Rev. 1986;38:2–30
  16. Lane M, Vogal CL, Ferguson J, Dransow S, Saiers J, Hamm J, et al  Dronabinol and prochlorperazine in combination for treatment of cancer. J. Pain Symptom Mange. 1991;6:352–359
  17. Mattes RD, Engelman K, Shaw LM, Elsoholy MA. Cannabinoids and appetite stimulation. Pharmacol. Biochem. Behav. 1994;49:187–195
  18. McFadden E. Asthma. In: Harrison’s Principles of Internal Medicine. 12th edn.. New York: McGraw-Hill; 1991;p. 1047–1053
  19. Meinck HM, Schonle PW, Conrad B. Effect of cannabis on spasticity and ataxia in multiple sclerosis. J. Neurol. 1989;236:120–122
  20. Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of δ-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J. Palliative Care. 1994;10:14–18
  21. Orr LA, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch. Int. Med. 1980;140:1431–1433
  22. Petro DJ, Ellenberger CE. Treatment of human spasticity with δ-9-tetrahydrocannabinol. J. Clin. Pharmacol. :S. 1981;21:413S–416
  23. Sallan SE, Zinberg NE, Frei E. antiemetic effect of δ-9-tetrahydrocaanabinol I patients receiving cancer chemotherapy. New. Engl. J. Med. 1975;293:795–797
  24. Schaeffer J, Andrysion T, Ungerleider JT. Cognition and long-term use of ganja (Cannabis). Science. 1981;213:465–466
  25. Schwartz RH. Marijuana as an antiemetic drug: How useful is it today? Opinions from clinical oncologists. J. Addict. Dis. 1994;13(1):53–65
  26. Ungerleider JT, Andrysiak Y, Fairbanks L, Ellison GW, Myers LW. δ-9-THC in the treatment for spasticity associated with multiple sclerosis. Adv Alcohol Substance Abuse. 1987;7(1):39–50
  27. Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. New York State J. Med. 1988;88:525–528

PII: S0376-8716(99)00076-9

Drug and Alcohol Dependence
Volume 58, Issue 1 , Pages 3-7 , 1 February 2000

Article Tools